In today's top stories related to Alphabet Inc. GOOG, we delve into regulatory challenges and a promising partnership in the healthcare sector.
Regulatory Hurdles:
Agence France-Presse (AFP) has initiated legal proceedings against Elon Musk's X social media platform, previously known as Twitter, accusing it of neglecting to negotiate potential compensation for the distribution of AFP's content.
This lawsuit underscores the regulatory risks that Alphabet faces regarding content moderation and remuneration for news. France's copyright law, enacted in 2019, mandates major online platforms to negotiate with publishers for compensation for news content.
Musk responded to AFP's lawsuit, challenging the concept of paying for traffic to their site, which generates advertising revenue.
In 2021, Google was penalized €500 million by France's antitrust watchdog for non-compliance with orders related to negotiations with news publishers.
However, Google has since pledged to resolve the dispute and has reached agreements with AFP and other French news organizations, Insurance Journal reports.
Expanding Partnerships:
Cognizant Inc CTSH and Google Cloud are broadening their collaboration to harness generative AI technology for healthcare solutions.
The partnership will focus on transforming administrative processes and enhancing patient engagement.
By leveraging Google Cloud's Vertex AI platform and Cognizant's AI expertise, the collaboration aims to drive cost optimization, business efficiencies, and superior experiences for healthcare clients.
The use of large language models (LLMs) can simplify complex administrative tasks, leading to reduced manual workloads, improved accuracy, and lower costs.
This expanded partnership underscores the potential of generative AI in healthcare and highlights Google Cloud's commitment to assisting healthcare organizations in transforming their operations, Techradar reports.
Disclaimer: This article was developed with the aid of artificial intelligence and Ultima Insights and underwent an editorial review.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.